Spire Healthcare Group (LSE:SPI) 5-Year Yield-on-Cost % : 1.02 (As of May. 26, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Spire Healthcare Group 5-Year Yield-on-Cost %?

Spire Healthcare Group's yield on cost for the quarter that ended in Dec. 2023 was 1.02.

The historical rank and industry rank for Spire Healthcare Group's 5-Year Yield-on-Cost % or its related term are showing as below:

LSE:SPI' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.19 Med: 1.61 Max: 7.22
Current: 1.02

During the past 13 years, Spire Healthcare Group's highest Yield on Cost was 7.22. The lowest was 0.19. And the median was 1.61.

LSE:SPI's 5-Year Yield-on-Cost % is ranked worse than
75.67% of 263 companies
in the Healthcare Providers & Services industry
Industry Median: 2.41 vs LSE:SPI: 1.02

Competitive Comparison of Spire Healthcare Group's 5-Year Yield-on-Cost %

For the Medical Care Facilities subindustry, Spire Healthcare Group's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spire Healthcare Group's 5-Year Yield-on-Cost % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Spire Healthcare Group's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Spire Healthcare Group's 5-Year Yield-on-Cost % falls into.

Spire Healthcare Group 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Spire Healthcare Group is calculated as

Yield-on-Cost

Dividend Yield %

Dividend Growth Rate)^5

Spire Healthcare Group (LSE:SPI) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Spire Healthcare Group 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Spire Healthcare Group's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.

Spire Healthcare Group (LSE:SPI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Spire Healthcare Group PLC (LSE:SPI) » Definitions » 5-Year Yield-on-Cost %

Comparable Companies

Traded in Other Exchanges

SPIl:UK S00:Germany

Address

3 Dorset Rise, London, GBR, EC4Y 8EN

Website

https://www.spirehealthcare.com

Spire Healthcare Group PLC is an independent hospital group in the United Kingdom, with 40 private hospitals and eight clinics. It is a private provider, by volume, of knee and hip operations in the United Kingdom. The Group is a well-located and scalable hospital have delivered successful and award-winning clinical outcomes, positioning the Group well with patients, Consultants, the NHS, GPs and Private Medical Insurance providers. It treats patients through a variety of routes including PMI, Self-pay and the NHS, providing the Group with diversified access to the expected growth opportunities in the UK healthcare market, which faces significant supply challenges as a result of NHS budget constraints and increasing demand from a growing population with longer life expectancy.